the latest market report published by credence n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Wilson’s Disease Drugs Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025 PowerPoint Presentation
Download Presentation
Wilson’s Disease Drugs Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025

Loading in 2 Seconds...

play fullscreen
1 / 4

Wilson’s Disease Drugs Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025 - PowerPoint PPT Presentation


  • 1 Views
  • Uploaded on

Wilson’s Disease Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/wilsons-disease-drugs-market

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Wilson’s Disease Drugs Market Growth, Future Prospects & Competitive Analysis, 2016 - 2025' - ConsuellaHunter


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
the latest market report published by credence

The latest market report published by Credence Research, Inc. “Wilson’s Disease

Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 -

2025,” the global Wilson’s disease drugs market was valued at US$ 372.5 Mn in 2016, and

is expected to reach US$ 592.8 Mn by 2025 expanding at a CAGR of 5.19 % from 2017 to

2025.

Market Insights

Pharmaceutical manufacturers are currently focusing in addressing the abnormal copper

metabolism to prevent the excessive deposition of copper in liver and other body organs.

WTX101 also known as bis-choline tetrathiomolybdenate developed by Wilson

Therapeutics AB is showing promising results in the phase 3 clinical trial study for

treatment of Wilson’s disease. It is the first novel copper protein binding agent with

unique mechanism of action. WTX101 has high specificity for copper and forms copper

protein complexes and provides alternative mechanism for the transport of copper

protein transport. Excessive copper levels are reduced in the blood and liver cells and

promotes biliary excretion of copper. Gene therapy is also a feasible option which will

transport functional ATPB7 gene via gene vectors.

Browse the full report Wilson’s Disease Drugs Market - Growth, Future Prospects,

Competitive

Analysis,

at http://www.credenceresearch.com/report/wilsons-disease-drugs-market

Chelators are the first line of treatment for disease management of Wilson’s disease. They

prevent the excessive deposition of copper in liver cells by expediting urine excretion of

copper. Zinc is used in patients non-reactive to chelators therapy. It has less adverse

events and used in long term therapy of Wilson’s disease.

The hepatic conditions are first diagnosed in patients suffering with Wilson’s disease due

to large accumulation of copper in the liver cells causing an increase in aspartate

aminotransferase and alanine aminotransferase. Neuropsychiatric symptoms are

manifested in the later stages of the disease with patient showing symptoms of seizures,

ataxia and tremors.

North America currently enjoys the leading position in Wilson’s disease treatment drugs

market on account of rising prevalence of Wilson’s disease in Caucasian population and

supportive regulatory environment provided by the USFDA for drugs employed in

treatment of Wilson’s disease. Recent technological advancement in laboratory

diagnostics in Asia Pacific has resulted in accurate diagnosis of patients suffering with

Wilson’s disease. Asia Pacific has tremendous opportunity for its established generic

market to manufacture drugs which are otherwise imported from western countries.

The pharmaceutical companies proactive in the treatment of Wilson’s disease are

Kadmon Holdings, Inc., Valeant Pharmaceuticals International, Inc., Merck & Co., Noble

Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., VHB Life

Sciences, Inc. and Wilson Therapeutics AB.

2017

2025

key market movements accurate diagnosis

Key Market Movements:

Accurate diagnosis of symptoms has brought enormous patients suffering with

Wilson’s disease in drug treatment regimen

Orphan disease status has acquired supportive regulatory milieu for the novel drug

discovery and development of Wilson’s disease

Enormous opportunity for major pharma players to conduct clinical trials and

establish R&D centers in developing nations with unmet medical needs

 Related

https://www.credenceresearch.com/industry/pharmaceuticals-market

Table of Content

 Chapter 1. Preface

1.1. Report Scope and Description

1.2. Research Methodology

1.2.1. Phase I-Secondary Research

1.2.2. Phase II-Primary Research

1.2.3. Phase III-Expert Panel Review

1.2.4. Assumptions

1.2.5. Approach Adopted

Chapter 2. Executive Summary

2.1. Global Wilson’s Disease Treatment Drugs Market Portraiture

2.1.1. Global Wilson’s Disease Treatment Drugs Market, by Indication, 2016 (Value

%)

2.1.2. Global Wilson’s Disease Treatment Drugs Market, by Drug Class, 2016

(Value %)

2.1.3. Global Wilson’s Disease Treatment Drugs Market, by Geography, 2016

(Value %)

Chapter 3. Wilson’s Disease Treatment Drugs Market: Dynamics and

Future Outlook

3.1. Market Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography

3.6. Top 3 Countries: Global Wilson’s Disease Drugs Market, 2015-2025 (US$ Mn)

3.7. Competitive Landscape : Global Wilson’s Disease Drugs Market, by Key

Players, 2015-2025 (US$ Mn)

Chapter 4. Global Wilson’s Disease Drugs Market, by Indication, 2015

– 2025 (US$ Mn)

Reports-

4 1 overview 4 2 attractive investment

4.1. Overview

4.2. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market, by

Indication, 2016

4.3. Hepatic

4.4. Neuropsychiatric

4.5. Ophthalmic

4.6. Others (Heart and Kidney Complications)

Chapter 5. Global Wilson’s Disease Drugs Market, by Drug Class, 2015

– 2025 (US$ Mn)

5.1. Overview

5.1.1. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market,

by Drug Class, 2016

5.2. Chelators

5.2.1. Penicillamine

5.2.2. Trientine

About Us:

Credence Research is a worldwide market research and counseling firm that serves

driving organizations, governments, non-legislative associations, and not-for-benefits.

We offer our customers some assistance with making enduring enhancements to their

execution and understand their most imperative objectives. Over almost a century, we’ve

manufactured a firm extraordinarily prepared to this task.

Latest Report

https://www.credenceresearch.com/report/gasket-and-seals-market

https://www.credenceresearch.com/report/metabolomics-market

https://www.credenceresearch.com/report/malic-acid-market

Media Contact

Name: Chris Smith

designation global sales manager

Designation: Global Sales Manager

Ph: 1-800-361-8290

Email: sales@credenceresearch.com

Web: http://www.credenceresearch.com/